Beijing Yuanfang Tongda Pharmaceutical Technology Co., Ltd.

To study the pharmacokinetic characteristics of the test preparation (Tiopronin tablets, specification 0.1g, produced by Huayi Pharmaceutical Technology (Anhui) Co., Ltd.) and the reference preparation (Tiopronin tablets, specification 100mg, trade name: Thiola, produced by Viatris Pharmaceutical Co., Ltd.) after a single oral administration in healthy participants under fasting state, compare the bioequivalence of the test preparation and the reference preparation, and study the safety of the drug in healthy participants.

A single-center, randomized, open-label, four-period completely repeated crossover design and single-dose design were used to compare the differences in absorption extent and rate between the compound glycyrrhizic acid tablets (specifications: each tablet contains 35 mg monoammonium glycyrrhizic acid (25 mg glycyrrhizic acid), 25 mg glycine, and 25 mg DL-methionine) provided by Beijing Yuanfangtongda Pharmaceutical Technology Co., Ltd. and the compound glycyrrhizic acid tablets (specifications: each tablet contains 35 mg monoammonium glycyrrhizic acid (25 mg glycyrrhizic acid), 25 mg glycine, and 25 mg DL-methionine; trade name: Minophagen®/Stronger Neo-Minophagen C®) certified by Minophagen Pharmaceutical Co., Ltd. under fasting and postprandial administration conditions in healthy people, and to evaluate the safety and tolerability of the compound glycyrrhizic acid tablets provided by Beijing Yuanfangtongda Pharmaceutical Technology Co., Ltd. and the compound glycyrrhizic acid tablets certified by Minophagen Pharmaceutical Co., Ltd.

To study the pharmacokinetic characteristics of the test preparation (Tiopronin tablets, specification 0.1g, produced by Huayi Pharmaceutical Technology (Anhui) Co., Ltd.) and the reference preparation (Tiopronin tablets, specification 100mg, trade name: Thiola, produced by Viatris Pharmaceutical Co., Ltd.) after a single oral administration in healthy participants in the postprandial state, to compare the bioequivalence of the test preparation and the reference preparation, and to study the safety of the drugs in healthy participants.